Compare · AMGN vs TARA
AMGN vs TARA
Side-by-side comparison of Amgen Inc. (AMGN) and Protara Therapeutics Inc. (TARA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and TARA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $202.95B, about 898.3x TARA ($225.9M).
- Over the past year, AMGN is up 22.7% and TARA is up 20.6% - AMGN leads by 2.1 points.
- TARA has been more active in the news (3 items in the past 4 weeks vs 1 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 6 for TARA).
- Company
- Amgen Inc.
- Protara Therapeutics Inc.
- Price
- -
- -
- Market cap
- $202.95B
- $225.9M
- 1M return
- +6.98%
- -0.25%
- 1Y return
- +22.68%
- +20.57%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2014
- News (4w)
- 1
- 3
- Recent ratings
- 25
- 6
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Protara Therapeutics Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Latest AMGN
- FDA Approval for REPATHA issued to AMGEN INC
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
Latest TARA
- Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.
- CEO and President Shefferman Jesse gifted 30,000 shares, exercised 215,687 shares at a strike of $1.91 and sold $882,160 worth of shares (215,687 units at $4.09), decreasing direct ownership by 4% to 691,832 units (SEC Form 4)
- Protara Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Director Levy Richard S
- SEC Form 4 filed by Director Solomon Michael Edward
- SEC Form 4 filed by Director Smith Cynthia
- SEC Form 4 filed by Director Sargen Gregory
- SEC Form 4 filed by Director Huang Jane
- SEC Form 4 filed by Director Flannelly Barry P
- SEC Form 4 filed by Director Garceau Roger